EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC 4.0

Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC

Masatoshi Kudo

Liver Cancer · 05.03.2026 · 15 (2) · 169-177

DOI: 10.1159/000551332 ↗

Kurz gefasst

Editorial in der Zeitschrift Liver Cancer, online erschienen am 05.03.2026. Verfasst von Masatoshi Kudo. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Cancer-free with drug-free statusCurative conversionHepatocellular carcinomaPathological complete responseSequential immune checkpoint inhibitor plus anti-VEGF/TKI therapy

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

Zitieren

APA

Kudo, M. (2026). Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC. Liver Cancer, 15(2), 169-177. https://doi.org/10.1159/000551332

Vancouver

Kudo M. Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC. Liver Cancer. 2026;15(2):169-177. doi:10.1159/000551332

BibTeX
@article{Kudo2026,
  author = {Kudo, Masatoshi},
  title = {Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC},
  journal = {Liver Cancer},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {169--177},
  doi = {10.1159/000551332}
}
Kostenlos starten →